Skip to main content
Clinical Trials/NCT02025478
NCT02025478
Completed
Not Applicable

A Pilot Study of Enteral Donor Human Milk in Young Children Receiving Bone Marrow Transplantation

Children's Hospital Medical Center, Cincinnati1 site in 1 country11 target enrollmentMay 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bone Marrow Transplant- Autologous or Allogeneic
Sponsor
Children's Hospital Medical Center, Cincinnati
Enrollment
11
Locations
1
Primary Endpoint
Percentage of lactobacillales
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The investigators hypothesize that children receiving human milk will maintain a greater diversity of helpful bacteria in their gut and have lower levels of inflammatory proteins in the blood compared with children not receiving human milk.

Detailed Description

The investigators hypothesize that the gut microbiota during bone marrow transplant could be influenced by administration of enteral donor breast milk. This study will attempt to address this hypothesis, by feeding donor breast milk to young children undergoing transplant, and serially comparing the gut micobiota in children receiving human milk, with those receiving conventional feeding.

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
January 2014
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Children less than 5 years old receiving transplant (autologous or allogeneic)
  • Parents must give informed consent

Exclusion Criteria

  • Failure to meet inclusion criteria

Outcomes

Primary Outcomes

Percentage of lactobacillales

Time Frame: 21 days after transplant

Bar charts to indicate types and percentage of bacteria in stool samples - will quantify the bacterial diversity using the Shannon index and bacterial chaos using the Bray-Curtis time index.

Secondary Outcomes

  • Levels of pro-inflammatory cytokines(Weekly during study course; up to approximately one year)
  • Incidence of graft versus host disease (GVHD)(through study course; approximately one year)
  • Incidence of bacteremia(through day 14 post transplant)

Study Sites (1)

Loading locations...

Similar Trials